Enliven Therapeutics (NASDAQ: ELVN) proposed 15,000-share sale via Jefferies

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. submitted a notice relating to the proposed sale of 15,000 common shares through Jefferies LLC. The filing lists the security type as common (related to stock options dated 08/09/2022).

The excerpt also shows multiple completed dispositions by Helen Collins during Feb–Apr 2026, including transactions of 45,000, 29,871, 10,129, 5,000, 40,000, and 5,000 shares on specific dates with corresponding proceeds shown.

Key Figures

Proposed resale: 15,000 shares Related grant date: 08/09/2022 Disposition example: 45,000 shares +3 more

6 metrics

Proposed resale 15,000 shares common shares to be sold through Jefferies LLC

Related grant date 08/09/2022 stock options date linked to the 15,000 shares

Disposition example 45,000 shares sale by Helen Collins on <date>02/17/2026</date>

Proceeds example $1,177,863.50 proceeds reported for Helen Collins sale on <date>02/17/2026</date>

Disposition example 40,000 shares sale by Helen Collins on <date>03/25/2026</date>

Proceeds example $1,404,022.40 proceeds reported for Helen Collins sale on <date>03/25/2026</date>

Key Terms

Form 144, stock options, Jefferies LLC

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

stock options financial

"08/09/2022 | Stock Options | Enliven Therapeutics, Inc."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Jefferies LLC financial

"Common | Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	15000	620100.00	61000000	05/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics, Inc.			15000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	02/17/2026	45000	1177863.50
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	03/09/2026	29871	896809.86
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	03/10/2026	10129	305826.52
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	03/17/2026	5000	138799.90
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	03/25/2026	40000	1404022.40
Helen Collins 6200 Lookout Road First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	04/17/2026	5000	238352.40

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Enliven Therapeutics' Form 144 for ELVN report?

It reports a proposed resale of 15,000 common shares through Jefferies LLC. The filing identifies the shares as from stock options dated 08/09/2022, and lists recent completed dispositions by a holder, Helen Collins.

Who is the selling agent named in the Enliven Therapeutics notice?

The selling broker listed is Jefferies LLC. The entry pairs Jefferies with the 15,000-share notice and provides an address for Jefferies on the cover information in the excerpt.

What recent transactions by Helen Collins are shown in the filing?

The excerpt shows multiple sales by Helen Collins between 02/17/2026 and 04/17/2026, including dispositions of 45,000, 29,871, 10,129, 5,000, 40,000, and 5,000 shares with listed proceeds.

Are the proceeds from the listed sales disclosed in the Form 144 excerpt?

Yes. Each listed Helen Collins disposition in the excerpt shows a cash figure alongside the shares, for example $1,177,863.50 and $1,404,022.40, linked to specific sale dates.